# Accendra Health, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Accendra Health, Inc).

## Overview

Accendra Health, Inc. (f/k/a Owens & Minor, Inc.) is a U.S.-based home healthcare company built around its Patient Direct operations and the Apria and Byram Healthcare brands. The company rents and sells durable medical equipment and ships recurring disposable medical supplies to patients’ homes, supporting chronic and complex conditions such as diabetes, sleep apnea, respiratory disease, ostomy, wound care, and urology needs. Its economic model is tightly linked to third-party reimbursement, with payments coming from Medicare, Medicaid, managed care plans, and commercial insurers, alongside patient co-pays. In late 2025, Accendra sold its Products & Healthcare Services distribution/manufacturing business and retained a 5% equity interest, simplifying the company around patient-direct care delivery and reimbursement-driven revenue.

## Products & services

• Diabetes supplies delivered to patients (testing & related consumables)
• Sleep therapy equipment and supplies (e.g., CPAP-related)
• Home respiratory therapy equipment (incl. non-invasive ventilation)
• Ostomy supplies and ongoing replenishment programs
• Wound care supplies and home-delivery fulfillment
• Urology supplies and catheter-related disposables
• Reimbursement, billing, and collections support for complex payors

- **Diabetes** (28%) — Home-delivered diabetes supplies and related recurring consumables.
- **Sleep therapy** (27%) — Sleep apnea therapy equipment and resupply programs for masks and accessories.
- **Home respiratory therapy** (16%) — Respiratory equipment and services for in-home treatment, including ventilation-related products.
- **Ostomy** (7%) — Ostomy products and recurring supply fulfillment to patients and agencies.
- **Wound care** (7%) — Wound care supplies and related home-delivery fulfillment.
- **Urology** (4%) — Urology supplies such as catheter-related disposables and replenishment programs.
- **Other patient-direct supplies and services** (11%) — Other home medical supplies and patient-direct services not captured above.

- Diabetes supplies delivered to patients (testing & related consumables)
- Sleep therapy equipment and supplies (e.g., CPAP-related)
- Home respiratory therapy equipment (incl. non-invasive ventilation)
- Ostomy supplies and ongoing replenishment programs
- Wound care supplies and home-delivery fulfillment
- Urology supplies and catheter-related disposables
- Reimbursement, billing, and collections support for complex payors

## Customers

Accendra’s end users are primarily patients receiving care at home, but the economic buyer is often a third-party Payor that reimburses the claim. The company supplies equipment rentals/sales and recurring disposables either directly to patients or via home health agencies, with payments coming from managed care plans, Medicare, Medicaid (and similar state programs), private insurers, and patient co-pays. Referral sources (e.g., providers and care teams) are important for patient acquisition and are governed by healthcare fraud-and-abuse rules such as the Anti-Kickback Statute and Stark Law, which constrain commercial arrangements. Because reimbursement rates and coverage policies vary by Payor and product, changes in customer mix and payment methodologies can materially shift profitability and cash collection dynamics.

- **Third-party Payors (Medicare, Medicaid, managed care, commercial)** (primary) — Reimburse claims for DME and disposable supplies; drive pricing, coverage, and denial/collection risk.
- **Patients (direct-to-patient fulfillment)** (primary) — Receive rented/sold equipment and recurring supplies; pay co-pays and influence retention through service quality.
- **Home health agencies** (secondary) — Source supplies and equipment for patients under their care; value reliable fulfillment and documentation support.
- **Referral sources (providers, clinics, labs)** (secondary) — Generate patient referrals within regulatory constraints; critical to volume in sleep and respiratory pathways.

- Patients needing chronic home care supplies (convenience + continuity of care)
- Managed care plans reimbursing DMEPOS and disposable supply claims
- Medicare as a major Payor; subject to DMEPOS competitive bidding dynamics
- State Medicaid programs with state-specific coverage and billing rules
- Commercial insurers/private payors with negotiated rates and denials risk
- Home health agencies purchasing/routing supplies for patients at home
- Patients/secondary payors paying co-pays and out-of-pocket balances

## Geography

Accendra is headquartered in Richmond, Virginia and operates as a nationwide U.S. provider focused on care delivery beyond the hospital. The company’s model depends on distributed fulfillment and service capabilities to reach patients in their homes and to support recurring resupply programs. While historical disclosures reference international operating risks (e.g., trade regulations and foreign currency), the post-2025 portfolio is centered on U.S. patient-direct operations after the sale of the Products & Healthcare Services business. Geographic footprint matters mainly through state-by-state reimbursement rules (especially Medicaid), licensing requirements, and local competitive intensity in home healthcare markets.

- United States nationwide home-delivery and service footprint
- Headquarters in Richmond, Virginia (corporate and governance center)
- State-level Medicaid and licensing differences affect operations and billing
- Local market fragmentation increases competition and referral dependence
- Exposure to trade/tariff dynamics via suppliers even with U.S. focus

## Strategy

The company’s most consequential recent strategic move was divesting the Products & Healthcare Services segment in December 2025, leaving a simpler, patient-direct operating model and a retained 5% equity interest in the sold business. Management emphasis is on scaling home healthcare categories with recurring utilization (diabetes, sleep therapy, respiratory) while improving operational efficiency through investments in patient service equipment and software. A core execution priority is tightening billing, claims submission, and collections processes to reduce denials and shorten collection cycles given complex reimbursement rules. Accendra also continues to evaluate acquisitions and integration opportunities, reflecting an industry where scale, payor contracting, and logistics capabilities can be differentiators.

- **Execute simplified Patient Direct operating model post-divestiture** (short-term) — Concentrates resources on home healthcare delivery and reimbursement execution.
- **Operational efficiency and capacity investments** (medium-term) — Equipment and software investments support service levels and scalable fulfillment economics.
- **Improve reimbursement execution and cash collections** (short-term) — Revenue and cash flow depend on accurate claims, fewer denials, and faster collections.

- Focus portfolio on Patient Direct after P&HS divestiture
- Invest in patient service equipment to support rental/resupply growth
- Improve billing/collections to reduce denials and DSO
- Strengthen referral relationships within Anti-Kickback/Stark constraints
- Pursue operational efficiency initiatives (fixed assets and software)
- Selective M&A to add scale/capabilities (integration execution critical)

## Risks

Accendra’s results are highly sensitive to reimbursement policy, Payor contracting, and competitive bidding dynamics in DMEPOS, which can reduce rates or restrict network access. The company also faces intense competition from national and local home healthcare providers and from adjacent entrants such as pharmacy benefit managers, increasing pricing pressure and raising the cost of acquiring/retaining referrals. Operationally, the business depends on key suppliers and third parties for components, finished goods, and services; disruptions, tariffs, or vendor concentration can impair service levels and margins. Company-specific risks include execution and residual obligations from the P&HS divestiture (including transitional services), cybersecurity threats to patient and claims systems, and regulatory/compliance exposure under healthcare fraud-and-abuse and licensing regimes.

- **Reimbursement and Payor policy risk (including DMEPOS competitive bidding)** [high] — Rates, coverage, and network decisions directly affect volumes, pricing, and denials.
- **Divestiture-related execution and retained obligations (P&HS sale)** [medium] — Transitional services, contract transfers, and retained liabilities can increase costs and disrupt focus.
- **Supplier and third-party dependence** [high] — Reliance on vendors for key components/finished goods exposes service levels and margins to disruptions.
- **Healthcare regulatory and fraud-and-abuse compliance** [critical] — Anti-Kickback and Stark constraints limit referral relationships; violations can trigger penalties and exclusion.
- **Cybersecurity and IT systems risk** [high] — Claims processing and patient data depend on secure, available systems; breaches can cause disruption and liability.

- Reimbursement cuts, denials, and DMEPOS competitive bidding pressure
- Payor network changes can reduce referrals or lower payment rates
- High competition and pricing pressure in fragmented home healthcare
- Supplier/vendor dependence and supply chain disruptions (incl. tariffs)
- Divestiture transition services can distract management and add costs
- Regulatory and licensing compliance (Anti-Kickback, Stark, Medicaid rules)
- Cyberattacks or system failures impacting claims and patient data
- Customer/product mix shifts can compress gross profit and cash collection

## Accounting

Revenue recognition is judgment-heavy because transaction prices are adjusted for variable consideration such as rebates, discounts, performance guarantees, and implicit price concessions, and management must constrain revenue to avoid future reversals. Because many arrangements involve third-party billing and uncertain reimbursement, adjustments are often recorded when cash is applied, claims are denied, or accounts are reviewed—creating period-to-period volatility in net revenue. The company’s balance sheet and earnings can also be affected by goodwill impairment testing, which relies on assumptions such as discount rates, terminal growth, and forecast cash flows; the company recorded a significant impairment in the Apria reporting unit in 2024. Analysts should also focus on accounts receivable and collections metrics (e.g., DSO) given the mix of Payors and co-pay collection practices, as changes in mix can alter both revenue estimates and working capital.

- **Revenue recognition with variable consideration (U.S. GAAP)** — Affects net revenue timing and volatility when claims are denied or settled.
- **Goodwill impairment (Apria reporting unit)** — Can create large non-cash charges; a $307m impairment was recorded in 2024.
- **Discontinued operations accounting for P&HS divestiture** — Impacts trend analysis and requires separating continuing vs discontinued performance.

- Revenue recognition uses estimates of variable consideration and constraints
- Net revenue can change when denials/cash application reveal true reimbursement
- Implicit price concessions and Payor mix affect reported net revenue
- Accounts receivable/DSO sensitive to billing accuracy and Payor behavior
- Goodwill impairment testing depends on discount rate and cash flow forecasts
- Discontinued operations presentation after P&HS sale affects comparability

---

*Last updated: 2026-09-24T11:21:37.744313+00:00*